Please select the option that best describes you:
What is your approach to systemic treatment of a rapidly progressing, symptomatic, unresectable MPNST arising from a plexiform neurofibroma in a patient with NF1?
Would you consider using the recently approved agent for symptomatic/unresectable PN, selumetinib prior to systemic chemotherapy in this setting?
Answer from: Medical Oncologist at Academic Institution
MPNST is a different ballgame than plexiform neurofibroma. Unfortunately, it is not chemotherapy-sensitive. We currently do not have a good option for MPNST. Perhaps clinical trial enrollment works best. We also do NGS to look for targets, apart from NF1. MEK inhibitors have been tried in the past w...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The activity of the MEK inhibitor is selective for the benign NF/PN. For the malignant transformation, with aggressive behavior, the SOC chemotherapy regimens are preferred. The SARC trial tested Dox/Ifex and Ifex/VP-16, and these remain the preferred front-line regimens.